West Pharmaceutical Services Inc. ($WST) Stock Forecast: Up 5.5% Today

What is West Pharmaceutical Services Inc.?

West Pharmaceutical Services, Inc. (WST) is a company that provides innovative solutions for injectable drug administration. The company is listed on the NYSE and is known for its high-quality products in the healthcare industry.

Why is West Pharmaceutical Services Inc. going up?

WST stock is up 5.5% on Jun 6, 2025 13:40

• The bullish movement in WST stock could be attributed to investors' optimism regarding the pending class action lawsuit.
• The reminder of the lawsuit deadline might have sparked confidence in the market, indicating that the company is taking necessary legal actions to address any potential issues.
• This proactive approach from West Pharmaceutical Services, Inc. could have reassured investors and led to increased buying interest, driving the stock price higher.
• Overall, the market's positive reaction to the news of the pending class action lawsuit reflects investor confidence in the company's ability to handle legal challenges effectively.

WST Price Chart

WST Technical Analysis

WST News

Levi & Korsinsky Reminds West Pharmaceutical Services, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 7, 2025 - WST - West Pharmaceutical Servs ( NYSE:WST )

NEW YORK, June 05, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in West Pharmaceutical Services, Inc. ( "West Pharmaceutical Services, Inc." or the "Company" ) WST of a class action securities lawsuit.

https://www.benzinga.com/pressreleases/25/06/g45799172/levi-korsinsky-reminds-west-pharmaceutical-services-inc-investors-of-the-pending-class-action-laws

Trending Today

Dogecoin ($DOGE) Crypto Forecast: Up 6.8% Today

Toncoin ($TON) Crypto Forecast: Up 5.0% Today

West Pharmaceutical Services Inc. Price History

03.00.2025 - WST Stock was up 3.6%

• Investors may have perceived WST's value favorably compared to its competitor Labcorp (LH).
• The contrast between LH and WST could have positioned WST as an underestimated stock, appealing to more investors.
• This positive perception of WST's value proposition likely contributed to the bullish performance of the stock today.

24.09.2024 - WST Stock was up 17.1%

• West Pharmaceutical Services, Inc. (WST) reported adjusted EPS of $1.85, surpassing expectations and showing resilience in its financial performance.
• Despite concerns about weakness in its Proprietary Products business and unfavorable currency movements, the company managed to exceed sales expectations, leading to the bullish movement in its stock.
• Investors may be optimistic about the company's ability to navigate challenges and deliver strong results, driving the stock price higher.

24.09.2024 - WST Stock was up 19.6%

• Despite the expected weakness in the Proprietary Products business, WST experienced a strong bullish movement.
• The unfavorable currency movements might not have had as significant an impact on the stock as anticipated.
• Investors may be optimistic about other aspects of WST's business or potential positive developments that are not captured.
• The market may have reacted positively to other factors such as strong demand for healthcare products or overall market conditions.

06.05.2025 - WST Stock was up 5.5%

• The bullish movement in WST stock could be attributed to investors' optimism regarding the pending class action lawsuit.
• The reminder of the lawsuit deadline might have sparked confidence in the market, indicating that the company is taking necessary legal actions to address any potential issues.
• This proactive approach from West Pharmaceutical Services, Inc. could have reassured investors and led to increased buying interest, driving the stock price higher.
• Overall, the market's positive reaction to the news of the pending class action lawsuit reflects investor confidence in the company's ability to handle legal challenges effectively.

24.01.2025 - WST Stock was up 5.3%

• WST experienced a bullish movement due to its identification as one of the top health care stocks with considerable growth potential this month.
• The stock being oversold in the health care sector attracted investors seeking undervalued opportunities.
• The Relative Strength Index (RSI), a momentum indicator, boosted trader confidence, resulting in increased buying pressure and a rise in the stock price.
• Positive market sentiment towards the health care sector and specific company analysis likely played a role in the notable bullish movement observed in WST.

13.01.2025 - WST Stock was down 32.6%

• Despite a positive performance in West Pharmaceutical's Q4 earnings, the stock showed a drop in pre-market trading.
• The decline in margins is considered a possible factor in the bearish movement, despite an increase in revenue in the Proprietary Products segment.
• Investors seemed to place more emphasis on the margin decrease rather than the overall earnings beat, resulting in a pessimistic market outlook and the downward trend in the stock price.

18.05.2024 - WST Stock was down 5.2%

• Investors may be eyeing WST due to its recent underperformance in the market, leading to a bearish movement.
• The key drivers of market outperformance and growth potential mentioned earlier may not have materialized as expected, causing a negative sentiment towards the stock.
• Market participants might be reevaluating their positions in WST, leading to a sell-off in the stock as investors adjust their expectations based on the company's performance.

25.06.2024 - WST Stock was down 8.4%

• Reported disappointing Q2 2024 earnings, with EPS of $1.52 missing estimates and revenue of $702.10 million falling short.
• Attributed the decline in performance to a decrease in demand for its products across segments, coupled with elevated customer destocking.
• The missed earnings and lowered outlook for 2024 could have led to a lack of investor confidence, resulting in a bearish movement in the stock price.
• Concerns may arise about the company's ability to drive growth and profitability in the face of challenging market conditions, leading to a sell-off of WST shares.

25.06.2024 - WST Stock was down 12.1%

• Today, West Pharmaceutical Services Inc. (WST) faced a substantial bearish movement in the stock market, potentially influenced by its Q2 earnings report:
• The company revealed an EPS of $1.51, missing estimates, and revenue of $702.1 million falling short, indicating a weaker financial performance than expected.
• The decline in Q2 profit and missed estimates likely contributed to investor concerns and the subsequent bearish market movement.
• Additionally, the impact of unfavorable currency movements on the company's top and bottom lines might have further dampened investor sentiment, resulting in the downward trend in WST stock.

04.03.2025 - WST Stock was down 6.5%

• Despite the positive surge in ProDex (PDEX) stock, WST experienced a bearish movement.
• The lack of indication for further gains in ProDex might have caused investors to reallocate their funds, leading to a sell-off in WST.
• Investors may have shifted focus from WST to ProDex, anticipating better returns based on the recent surge in PDEX stock price.
• This shift in market sentiment towards ProDex could have contributed to the bearish movement in WST as investors sought potentially more lucrative opportunities in the market.

22.03.2025 - WST Stock was up 5.4%

• WST had a strong bullish movement today due to expectations of strong segmental performance in the first quarter, driven by growth in pharmaceutical stabilization, biologics rebound, and contract manufacturing gains.
• The market is likely reacting positively to the potential growth and stability in the pharmaceutical sector, which is a key market for West Pharmaceutical Services.
• Investors are optimistic about the company's ability to capitalize on the increased demand for injectable drug administration solutions, especially in the current global health landscape.

13.01.2025 - WST Stock was down 35.7%

• Despite exceeding Q4 earnings expectations, West Pharmaceutical's stock experienced a decline attributed to weaker-than-anticipated guidance for 2025. This included adjusted EPS and revenue forecasts that missed consensus estimates.
• The market responded negatively to the company's reduced earnings and revenue projections for the upcoming year, resulting in a notable sell-off of WST stock.
• Investors reacted possibly due to disappointment stemming from the downward revision in West Pharmaceutical's future financial outlook. This sentiment drove the stock price lower during today's trading session.